Table 2.

Baseline characteristics, follow-up, and outcomes of 125 patients with NOS FSGS and 56 patients with collapsing FSGS according to exposure to immunotherapy with glucocorticoids and/or calcineurin inhibitors

Characteristics	Collapsing, n=56					NOS, n=125
	Immunotherapy		No Immunotherapy		P Value	Immunotherapy		No Immunotherapy		P Value
	n		n			n		n
Onset
Age, yr	37	29 (19–46)	19	34 (26–42)	0.63	86	33 (16–52)	39	48 (23–67)	<0.01
Women, %	37	73.0	19	52.6	0.15	86	44.2	39	43.6	>0.99
Black race, %	37	78.4	19	78.9	0.25	84	51.2	35	40.0	0.32
Hypertension, %	37	43.2	19	36.8	0.75	68	52.9	35	54.3	1.00
Serum creatinine, mg/dl	37	1.4 (1.0–2.3)	19	2 (1.5–3)	0.03	84	1.1 (0.8–1.6)	38	1.6 (1.1–2.2)	0.003
eGFR by MDRD equation, ml/min per 1.73 m2	36	54 (30–85)	17	35 (27–48)	0.04	83	66 (46–98)	38	45 (31–70)	<0.001
Up/c, g/g	20	10.5 (8.4–17.8)	4	3.1 (2.0–5.9)	<0.01	51	7.6 (4.0–11.6)	16	2.7 (1.9–5.5)	0.002
24-h Proteinuria, g/d	24	12.3 (6.5–14.7)	15	12.2 (4.4–15.0)	0.92	41	4.6 (2.7–12.0)	26	3.1 (1.6–6.0)	0.03
Serum albumin, g/dl	33	2.3 (1.9–2.9)	19	2.4 (2.0–3.5)	0.49	74	2.2 (1.6–3.5)	29	3.6 (3.3–4.0)	<0.001
Follow-up
Duration of follow-up, mo	37	74 (40–137)	19	36 (4–71)	0.003	86	68 (24–136)	39	76 (21–164)	0.89
RAAS inhibition, %	37	81.1	19	63.2	0.20	86	95.3	39	87.2	0.14
Outcomes
Remission, %	30	70.0	5	40.0	0.31	81	65.4	32	56.3	0.39
ESRD,a %	37	35.1	19	73.7	0.01	86	25.6	39	28.2	0.83

Continuous variables are expressed as medians (interquartile ranges). NOS, not otherwise specified; MDRD, Modification of Diet in Renal Disease, Up/c, urinary protein-to-creatinine ratio; RAAS, renin-angiotensin-aldosterone system.

^aAt last follow-up.